The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $17.29, up 1.65% from its previous closing price of $17.01. In other words, the price has increased by $1.65 from its previous closing price. On the day, 2.47 million shares were traded. ARQT stock price reached its highest trading level at $17.64 during the session, while it also had its lowest trading level at $16.91.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.97 and its Current Ratio is at 4.15. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.
Mizuho Upgraded its Neutral to Buy on January 03, 2024, whereas the target price for the stock was revised from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 24 ’25 when Watanabe Todd Franklin bought 1,500 shares for $17.52 per share.
Watanabe Todd Franklin sold 1,200 shares of ARQT for $21,137 on Mar 17 ’25. The insider now owns 928,914 shares after completing the transaction at $17.61 per share. On Mar 17 ’25, another insider, Watanabe Todd Franklin, who serves as the Officer of the company, bought 1,200 shares for $17.61 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 2051251072 and an Enterprise Value of 1933885056. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.44 while its Price-to-Book (P/B) ratio in mrq is 12.93. Its current Enterprise Value per Revenue stands at 9.84 whereas that against EBITDA is -15.373.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.65, which has changed by 0.8651564 over the last 52 weeks, in comparison to a change of 0.10838497 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $17.70, while it has fallen to a 52-week low of $6.99. The 50-Day Moving Average of the stock is 25.42%, while the 200-Day Moving Average is calculated to be 54.34%.
Shares Statistics:
It appears that ARQT traded 2.29M shares on average per day over the past three months and 3008190 shares per day over the past ten days. A total of 117.85M shares are outstanding, with a floating share count of 104.38M. Insiders hold about 12.02% of the company’s shares, while institutions hold 102.23% stake in the company. Shares short for ARQT as of 1740700800 were 19766505 with a Short Ratio of 8.63, compared to 1738281600 on 18914622. Therefore, it implies a Short% of Shares Outstanding of 19766505 and a Short% of Float of 20.549999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
